Shipped cold to your door  ·  Lyophilized vialsQuestions? WhatsApp +62 811 2120 5090
A small plate of grilled fish, steamed vegetables and rice on a wooden dining table by a window, with a glass of water and a linen napkin
News

CagriSema at ObesityWeek 2026: REDEFINE 9 results at lower doses

18 November 2026

The amylin pathway is back in the spotlight this week. On 14 November 2026, Novo Nordisk announced primary results from the Phase 3 REDEFINE 9 clinical trial of CagriSema, a fixed-dose combination of cagrilintide and semaglutide given once a week. The results were presented at ObesityWeek 2026 in Washington, D.C., and published the same day in The Lancet Diabetes & Endocrinology.

14 November 2026
Novo Nordisk announced primary REDEFINE 9 results, presented at ObesityWeek 2026 and published in The Lancet Diabetes & Endocrinology.
15 November 2026
Novo Nordisk presented a follow-up analysis of REDEFINE 1 on participants who responded early.
Status
The CagriSema application was filed with the US FDA in December 2025 and is under review. A decision is expected in the fourth quarter of 2026.
Source
Official Novo Nordisk releases via PR Newswire, 14 and 15 November 2026.

What REDEFINE 9 studied

REDEFINE 9 enrolled 309 adults with obesity, or with overweight plus at least one related condition, without diabetes. The study ran for 68 weeks, and all participants also followed a lifestyle program.

What makes it interesting: this is the first Phase 3 trial to assess CagriSema at two dose levels below the dose filed with the FDA. Each dose level was compared with a comparison group that received no active substance.

The numbers reported

How it was calculatedMiddle doseLowest doseComparison group
If all participants stayed on treatment to the end20.7%21.0%2.0%
All participants, whatever happened during the study19.4%18.6%4.6%
Average weight reduction in REDEFINE 9 at week 68

About half of CagriSema participants recorded a weight reduction of 20% or more: 51.3% at the middle dose and 48.3% at the lowest dose under the first calculation. Waist circumference came down by an average of 17.2 cm and 17.5 cm.

The release notes that the study was not designed to compare the two doses with each other, so the small gap between them is best read as equivalent results. The most frequently recorded complaints were digestive and mild to moderate, in line with earlier CagriSema studies.

REDEFINE 1 follow-up analysis: early response

A day later, on 15 November 2026, Novo Nordisk presented a follow-up analysis of REDEFINE 1, a 68-week study with 3,417 participants that used the dose filed with the FDA. CagriSema participants were grouped by their early response: those whose weight came down by at least 5% at week 8 were called early responders.

In total, 67.8% of CagriSema participants were early responders, with an average weight reduction of 25.4% at week 68. The group that responded more slowly recorded an average of 17.8%. The lead author stressed that these figures are hypotheses for further research, not a basis for changing treatment decisions. Individual responses vary, and every figure above is a study group average.

Why this matters for the amylin pathway

Cagrilintide is a long-acting amylin analog, while semaglutide acts on the GLP-1 receptor. The two reach satiety signals through different receptors, and REDEFINE 9 adds to the picture that this pairing works at more than one dose level. The molecule's profile is in Cagrilintide and the amylin pathway, and another name on the same pathway is covered in Eloralintide and the amylin pathway.

This year's ObesityWeek also brought news from another pathway. A summary of the retatrutide data presented at the same meeting is in the latest retatrutide data, November 2026.

Cagrilintide in the Peptivia catalog

CagriSema is Novo Nordisk's combination, pairing cagrilintide with semaglutide. In the Peptivia catalog, cagrilintide comes in a different pairing, Retatrutide + Cagrilintide in a single vial, so the study figures above belong to CagriSema. Why this pairing draws interest is covered in Retatrutide and Cagrilintide: why they are paired.

Details for each product are in the Peptivia catalog. If you have questions before ordering, our team is glad to help through Peptivia's official WhatsApp.

Frequently asked questions
What is CagriSema?

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist. It is developed by Novo Nordisk and given once a week in clinical trials.

What are the main REDEFINE 9 results?

At week 68, the two lower CagriSema dose levels recorded average weight reductions of 20.7% and 21.0% if all participants stayed on treatment to the end, compared with 2.0% in the comparison group. These are group averages, and individual responses vary.

When and where were the REDEFINE 9 results presented?

They were announced on 14 November 2026, presented at ObesityWeek 2026 in Washington, D.C., and published the same day in The Lancet Diabetes & Endocrinology.

What is CagriSema's status with the FDA?

Novo Nordisk filed the CagriSema application with the US FDA in December 2025. It is under review, and a decision is expected in the fourth quarter of 2026.

How does CagriSema differ from Retatrutide + Cagrilintide?

CagriSema pairs cagrilintide with semaglutide, which acts on one pathway, GLP-1. Retatrutide + Cagrilintide pairs cagrilintide with retatrutide, which acts on three pathways: GLP-1, GIP and glucagon. The REDEFINE 9 results are data for CagriSema.

Peptides in this article

Still deciding which one fits? Tell us your goal and we will help you narrow it down.

Chat on WhatsApp